[go: up one dir, main page]

MA35185B1 - Nouveaux composés en tant qu'inhibiteurs de diacylglycérol acyltransférase - Google Patents

Nouveaux composés en tant qu'inhibiteurs de diacylglycérol acyltransférase

Info

Publication number
MA35185B1
MA35185B1 MA36566A MA36566A MA35185B1 MA 35185 B1 MA35185 B1 MA 35185B1 MA 36566 A MA36566 A MA 36566A MA 36566 A MA36566 A MA 36566A MA 35185 B1 MA35185 B1 MA 35185B1
Authority
MA
Morocco
Prior art keywords
dgat
inhibitors
diacylglycerol acyltransferase
obesity
new compounds
Prior art date
Application number
MA36566A
Other languages
English (en)
Inventor
Donghui Qin
Mui Cheung
Hemant Joshi
Raghuram Tangirala
Sridhar Reddy Bethi
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of MA35185B1 publication Critical patent/MA35185B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La présente invention concerne de nouveaux composés qui sont des inhibiteurs de l'acide coenzyme a : diacylglycérol acyltransférase 1 (dgat-1), des compositions pharmaceutiques les incluant, des procédés de synthèse desdits composés et leurs applications thérapeutiques dans le traitement prophylactique ou thérapeutique de maladies liées aux dysfonctionnements de dgat-1 ou pour lesquels la modulation de l'activité de dgat-1 peut apporter un bénéfice thérapeutique, ce qui inclut sans y être limité les maladies suivantes : obésité, troubles liés à l'obésité, hypertriglycéridémie, hyperlipoprotéinémie, chylomicronémie, dyslipidémie, stéatose hépatique non alcoolique, diabète, insulinorésistance, syndrome métabolique, infection par le virus de l'hépatite c et acné ou autres troubles cutanés.
MA36566A 2011-05-20 2013-12-13 Nouveaux composés en tant qu'inhibiteurs de diacylglycérol acyltransférase MA35185B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1452DE2011 2011-05-20
US201161503728P 2011-07-01 2011-07-01
PCT/US2012/038523 WO2012162129A1 (fr) 2011-05-20 2012-05-18 Nouveaux composés en tant qu'inhibiteurs de diacylglycérol acyltransférase

Publications (1)

Publication Number Publication Date
MA35185B1 true MA35185B1 (fr) 2014-06-02

Family

ID=47217645

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36566A MA35185B1 (fr) 2011-05-20 2013-12-13 Nouveaux composés en tant qu'inhibiteurs de diacylglycérol acyltransférase

Country Status (34)

Country Link
US (4) US8859536B2 (fr)
EP (1) EP2710013B1 (fr)
JP (1) JP5844456B2 (fr)
KR (1) KR101919080B1 (fr)
CN (1) CN103703009B (fr)
AU (1) AU2012259044B2 (fr)
BR (1) BR112013029935B1 (fr)
CA (1) CA2836669C (fr)
CO (1) CO6811855A2 (fr)
CR (1) CR20130602A (fr)
CY (1) CY1118188T1 (fr)
DK (1) DK2710013T3 (fr)
DO (1) DOP2013000272A (fr)
EA (1) EA023030B1 (fr)
ES (1) ES2588748T3 (fr)
HR (1) HRP20161089T1 (fr)
HU (1) HUE028870T2 (fr)
IL (1) IL229488A (fr)
LT (1) LT2710013T (fr)
MA (1) MA35185B1 (fr)
ME (1) ME02479B (fr)
MX (1) MX346494B (fr)
MY (1) MY184553A (fr)
PE (1) PE20141204A1 (fr)
PH (1) PH12013502401A1 (fr)
PL (1) PL2710013T3 (fr)
PT (1) PT2710013T (fr)
RS (1) RS55006B1 (fr)
SG (1) SG195044A1 (fr)
SI (1) SI2710013T1 (fr)
SM (1) SMT201600328B (fr)
UA (1) UA111360C2 (fr)
WO (1) WO2012162129A1 (fr)
ZA (1) ZA201308664B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2710013T (lt) 2011-05-20 2016-09-12 Glaxosmithkline Intellectual Property (No. 2) Limited Naujieji junginiai kaip diacilglicerolio aciltransferazės inhibitoriai
RS58539B1 (sr) 2012-11-23 2019-04-30 Glaxosmithkline Llc Nova jedinjenja kao inhibitori diacilglicerin aciltransferaze
WO2014081996A1 (fr) * 2012-11-23 2014-05-30 Glaxosmithkline Llc Nouveaux composés en tant qu'inhibiteurs de diacylglycérol acyltransférase
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
CN103524431B (zh) * 2013-09-24 2016-01-13 西安交通大学 3-苄基-4-喹唑啉酮类化合物及其合成方法和应用
WO2015049667A1 (fr) 2013-10-03 2015-04-09 Glaxosmithkline Intellectual Property (No.2) Limited Nouveau composé inhibiteur de diacylglycérol acyltransférase
WO2015049668A1 (fr) 2013-10-03 2015-04-09 Glaxosmithkline Intellectual Property (No.2) Limited Nouveau composé utilisé en tant qu'inhibiteur de la diacylglycérol acyltransférase
CN103880757B (zh) * 2014-04-15 2016-02-24 上海毕得医药科技有限公司 一种5-羟基嘧啶-2-羧酸的合成方法
WO2016181409A1 (fr) 2015-05-11 2016-11-17 Cadila Healthcare Limited Magnésium saroglitazar pour le traitement du syndrome chylomicronémie
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
CN105732461A (zh) * 2016-02-03 2016-07-06 常州工程职业技术学院 5-甲氧基-6-卤代吲哚的制备方法
CN106083707B (zh) * 2016-06-01 2018-10-26 温州大学 一种非对称杂芳基硫醚的合成方法
CN107619928B (zh) * 2016-07-15 2020-08-07 中国科学院上海有机化学研究所 一种萃取组合物、萃取体系及其应用
CN107619932B (zh) * 2016-07-15 2020-08-07 中国科学院上海有机化学研究所 一种萃取组合物、萃取体系及其应用
RU2706655C1 (ru) * 2019-01-28 2019-11-19 Акционерное общество "Гознак" (АО "Гознак") Полимерсодержащее композиционное защищенное изделие

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090036425A1 (en) * 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
AU2009335843A1 (en) * 2008-12-19 2011-07-21 Abbvie Inc. Heterocyclic compounds and methods of use
WO2010086820A1 (fr) * 2009-02-02 2010-08-05 Pfizer Inc. Dérivés de 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazépin-6(5h)-yl)phényle
AR076126A1 (es) * 2009-03-18 2011-05-18 Schering Corp Compuestos biciclicos como inhibidores de diacilglicerol aciltransferasa
SG175287A1 (en) * 2009-04-24 2011-11-28 Hoffmann La Roche Inhibitors of bruton's tyrosine kinase
LT2710013T (lt) 2011-05-20 2016-09-12 Glaxosmithkline Intellectual Property (No. 2) Limited Naujieji junginiai kaip diacilglicerolio aciltransferazės inhibitoriai
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors

Also Published As

Publication number Publication date
CR20130602A (es) 2014-08-13
EP2710013A1 (fr) 2014-03-26
LT2710013T (lt) 2016-09-12
HUE028870T2 (en) 2017-01-30
NZ617991A (en) 2015-06-26
PE20141204A1 (es) 2014-10-05
MX346494B (es) 2017-03-21
MY184553A (en) 2021-04-02
US20160200736A1 (en) 2016-07-14
AU2012259044A1 (en) 2013-12-12
EA201391737A1 (ru) 2014-04-30
SG195044A1 (en) 2013-12-30
PL2710013T3 (pl) 2017-08-31
IL229488A (en) 2016-04-21
ME02479B (fr) 2017-02-20
PH12013502401A1 (en) 2015-10-07
EA023030B1 (ru) 2016-04-29
DK2710013T3 (en) 2016-09-26
CA2836669C (fr) 2019-03-19
PT2710013T (pt) 2016-09-28
WO2012162129A1 (fr) 2012-11-29
HK1194738A1 (zh) 2014-10-24
EP2710013A4 (fr) 2014-11-05
AU2012259044B2 (en) 2015-09-17
JP2014517839A (ja) 2014-07-24
US9273069B2 (en) 2016-03-01
US9040517B2 (en) 2015-05-26
SI2710013T1 (sl) 2016-10-28
EP2710013B1 (fr) 2016-06-29
CO6811855A2 (es) 2013-12-16
SMT201600328B (it) 2016-11-10
ZA201308664B (en) 2015-02-25
US20150225425A1 (en) 2015-08-13
MX2013013566A (es) 2014-01-08
US20140378434A1 (en) 2014-12-25
IL229488A0 (en) 2014-01-30
US20140080809A1 (en) 2014-03-20
BR112013029935B1 (pt) 2020-12-15
BR112013029935A2 (pt) 2016-09-20
DOP2013000272A (es) 2014-05-15
US9540400B2 (en) 2017-01-10
US8859536B2 (en) 2014-10-14
JP5844456B2 (ja) 2016-01-20
ES2588748T3 (es) 2016-11-04
UA111360C2 (uk) 2016-04-25
CN103703009B (zh) 2016-08-17
RS55006B1 (sr) 2016-11-30
CA2836669A1 (fr) 2012-11-29
CY1118188T1 (el) 2017-06-28
KR101919080B1 (ko) 2018-11-16
KR20140045415A (ko) 2014-04-16
HRP20161089T1 (hr) 2016-10-21
CN103703009A (zh) 2014-04-02

Similar Documents

Publication Publication Date Title
MA35185B1 (fr) Nouveaux composés en tant qu'inhibiteurs de diacylglycérol acyltransférase
EA032971B1 (ru) Соль берберина и урсодезоксихолевой кислоты и ее применение
BR112014016165A8 (pt) compostos de benzaldeído substituído e métodos para seu uso no aumento da oxigenação do tecido
EA201391786A1 (ru) Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2
EA201300558A1 (ru) Соединения и способы для купирования боли
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
MX2014014902A (es) Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas.
EA201301320A1 (ru) 4-арил-n-фенил-1,3,5-триазин-2-амины, которые содержат сульфоксиминную группу
EA201992607A1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
EP2855435A4 (fr) Amino-amides de type dendrimères possédant une activité de blocage des canaux sodiques pour le traitement de la sécheresse oculaire et d'autres maladies des muqueuses
EA201390826A1 (ru) ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA
GB2511685A (en) Muscarinic m1 receptor agonists
EA201491606A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201690521A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
EA201590562A1 (ru) Бензамиды
EA201400067A1 (ru) Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента
EA201491081A1 (ru) Композиции и способы для лечения заболеваний и расстройств печени
MX382630B (es) Compuestos de pirazol disustituidos para el tratamiento de enfermedades.
UA109414C2 (uk) Арильовані камфени та фармацевтична композиція на їх основі
WO2012142615A3 (fr) Auranofine et analogues d'auranofine utiles pour traiter une maladie proliférative et des troubles prolifératifs
EA201790315A1 (ru) Модуляторы x-рецепторов печени
FR2981936B1 (fr) Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
MX2014014066A (es) Compuestos de cromano.
EA201391724A1 (ru) Новые соединения в качестве ингибиторов диацилглицерин ацилтрансферазы
PH12014501443A1 (en) 1,3-diphenylpropane derivatives, preparations and uses thereof